Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Express Scripts
Dow
Colorcon
Medtronic

Last Updated: May 20, 2022

TRILEPTAL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Trileptal patents expire, and what generic alternatives are available?

Trileptal is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in TRILEPTAL is oxcarbazepine. There are twenty-one drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Trileptal

A generic version of TRILEPTAL was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.

  Sign up for a Free Trial

Drug patent expirations by year for TRILEPTAL
Drug Prices for TRILEPTAL

See drug prices for TRILEPTAL

Drug Sales Revenue Trends for TRILEPTAL

See drug sales revenues for TRILEPTAL

Recent Clinical Trials for TRILEPTAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen HospitalPhase 4
Collaborative Care Initiative, LLCPhase 4
Mid and South Essex NHS Foundation TrustPhase 2

See all TRILEPTAL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TRILEPTAL
Paragraph IV (Patent) Challenges for TRILEPTAL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRILEPTAL Oral Suspension oxcarbazepine 300 mg/5 mL 021285 1 2006-12-26
TRILEPTAL Tablets oxcarbazepine 150 mg, 300 mg and 600 mg 021014 1 2006-05-05

US Patents and Regulatory Information for TRILEPTAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRILEPTAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000 See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000 See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 See Plans and Pricing See Plans and Pricing
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRILEPTAL

See the table below for patents covering TRILEPTAL around the world.

Country Patent Number Title Estimated Expiration
Malaysia 117582 OXACARBAZEPINE FILM-COATED TABLETS See Plans and Pricing
Slovenia 0966287 See Plans and Pricing
Norway 993919 See Plans and Pricing
Norway 20022849 See Plans and Pricing
Turkey 200201459 See Plans and Pricing
Slovenia 1239832 See Plans and Pricing
Czech Republic 9902879 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
Colorcon
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.